Results 11 to 20 of about 26,086 (200)

The dual role of TIGIT in regulatory and effector T cells in chronic liver disease [PDF]

JHEP Reports
Background & Aims: Effective control of chronic liver diseases (CLD) requires suppression of effector T cells by CD4+CD25+CD127low regulatory T cells (Tregs).
Amber G. Bozward, Scott P. Davies, Rémi Fiancette, Grace E. Wootton, Sian Faustini, Hin Fai Kwok, Naomi Richardson, Sean M. Morris, Kayani Kayani, Gary Middleton, Ye H. Oo   +10 more
doaj   +2 more sources

A novel scoring system for TIGIT expression in classic Hodgkin lymphoma [PDF]

Scientific Reports, 2021
Clinical use of immune-checkpoints inhibitors (anti PD-1/PD-L1) resulted very effective for the treatment of relapsed/refractory classic Hodgkin Lymphoma (CHL).
Ombretta Annibali, Antonella Bianchi, Alba Grifoni, Valeria Tomarchio, Mariantonietta Tafuri, Martina Verri, Giuseppe Avvisati, Anna Crescenzi   +7 more
doaj   +2 more sources

Combining TIGIT blockade with IL‐15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma

Clinical and Translational Medicine
Background T‐cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT) is an immune checkpoint molecule that suppresses CD8+ T‐cell function in cancer.
Baohong Luo, Yu Sun, Qinru Zhan, Yuting Luo, Yu Chen, Tongze Fu, Tiantian Yang, Lijuan Ren, Zhongpeng Xie, Xiaohua Situ, Bixia Liu, Kejing Tang, Zunfu Ke   +12 more
doaj   +2 more sources

TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies

Cell Death and Disease
TIGIT immune checkpoint (IC) has attracted great interest in recent years. It belongs to the PVR-like protein family, and it inhibits T and NK cell cytotoxic activities.
Haozhe Cui, Mawieh Hamad, Eyad Elkord
doaj   +2 more sources

CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells. [PDF]

Adv Sci (Weinh)
AARS2 functions as an intracellular lactate sensor and lactyltransferase, catalyzing CD112 K412 lactylation to block ubiquitination‐dependent degradation and stabilize CD112. This pathway suppresses CD8+ T‐cell and NK‐cell cytotoxicity, enabling dual immune evasion.
Xu Z, Zhang X, Dong F, Shen N, Zhou J, Xi Z, Wu Z.   +6 more
europepmc   +2 more sources

Intratumoral TIGIT blockade augments antitumor responses and bypasses increased functionality of peripheral TIGIT+ NK cells in mouse and human models of bone and soft tissue sarcoma. [PDF]

J Immunother Cancer
Background TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a key exhaustion marker of intratumoral natural killer (NK) cells, but results from clinical trials with TIGIT blockade have been ...
Lammers ML, Sholevar CJ, Karimzadeh M, Razmara AM, Cruz SM, Purl MC, Liu NM, Bakke D, Plagens RN, Elliott A, Sheng MK, Dongen CV, Tran T, Trinh AT, Nielsen RN, Kotamraju T, Farley LE, Iranpur KR, Mukarrama T, Gronchi A, Riedel RF, Monjazeb AM, Thorpe SW, Darrow MA, Kim J, Murphy WJ, Judge SJ, Canter RJ.   +27 more
europepmc   +2 more sources

TIGIT immunostaining.

, 2022
TIGIT expression in colorectal cancer (CRC). TIGIT expression in human CRC tissues. Representative case with high (grade 1–3) and low (grade 0) TIGIT expression.
Hiromitsu Iwamoto (12289515), Fumiyoshi Kojima (2575441), Hiroki Yamaue (277099), Ibu Matsuzaki (2575435), Kenji Matsuda (1277604), Yuichi Takahashi (3015525), Yasuyuki Mitani (4373491), Shin-ichi Murata (25100), Daisuke Murakami (6106532), Yuki Nakamura (138324), Yuki Mizumoto (10918160), Ryuta Iwamoto (11832439)   +11 more
core   +1 more source

Overall survival curve for TIGIT.

, 2022
Overall survival curve for TIGIT.
Hiromitsu Iwamoto (12289515), Fumiyoshi Kojima (2575441), Hiroki Yamaue (277099), Ibu Matsuzaki (2575435), Kenji Matsuda (1277604), Yuichi Takahashi (3015525), Yasuyuki Mitani (4373491), Shin-ichi Murata (25100), Daisuke Murakami (6106532), Yuki Nakamura (138324), Yuki Mizumoto (10918160), Ryuta Iwamoto (11832439)   +11 more
core   +1 more source

TIGIT as an emerging immune checkpoint [PDF]

, 2019
T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy.
Harjunpaeae, H., Guillerey, C., Harjunpää, H.   +2 more
core   +1 more source

TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma

iScience, 2023
Summary: TIGIT is a receptor on human natural killer (NK) cells. Here, we report that TIGIT does not spontaneously induce inhibition of NK cells in glioblastoma (GBM), but rather acts as a decoy-like receptor, by usurping binding partners and regulating ...
Kyle B. Lupo, Sandra Torregrosa-Allen, Bennett D. Elzey, Sagar Utturkar, Nadia A. Lanman, Aaron A. Cohen-Gadol, Veronika Slivova, MacKenzie McIntosh, Karen E. Pollok, Sandro Matosevic   +9 more
doaj   +1 more source